Sarcoma, Alveolar Soft Part — Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
Citation(s)
A Phase II Trial In Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, With Cross-Over at Disease Progression